公司擁有ABGENT、B-bridge、IBL-America、R&D、CST、MBL、SAB、KPL、Santa、Abnova、LifeSpan等G蛋白偶聯(lián)受體109A抗體品牌全年代理權(quán)，價(jià)格行業(yè)優(yōu)勢(shì)明顯。
英文名稱 Anti-GPR109A/HM74A
中文名稱 G蛋白偶聯(lián)受體109A抗體 
G蛋白偶聯(lián)受體109A抗體 別 名 G-protein coupled receptor 109A; GPR109A; HM74a; HM74b; NIACR1; Puma-g; PUMAG; Niacr1; Niacin receptor 1; Nicotinic acid receptor; G-protein coupled receptor 109; G-protein coupled receptor HM74; G protein coupled receptor HM74a; G protein coupled receptor Hm74b; Protein PUMA-G; Interferon gamma inducible gene Puma g; Nicotinic acid receptor 1; Nicotinic acid receptor; Puma g; Pumag; rHM74b; HCAR2_HUMAN .
濃 度 1mg/1ml
規(guī) 格 0.2ml/200μg
抗體來(lái)源 Rabbit
克隆類型 polyclonal
交叉反應(yīng) Human, Mouse, Rat, Pig, Rabbit
產(chǎn)品類型 一抗
研究領(lǐng)域 免疫學(xué)
46915L-HDC （L-Histidine decarboxylase） L-組氨酸脫羧酶抗原 0.5mg
46916LIF peptide 白血病抑制因子抗原 0.5mg
46917LIFR/CD118 peptide 白血病抑制因子受體抗原 0.5mg
46918Lingo-1 Nogo受體作用蛋白抗原 0.5mg
46919LIS1（Lissencephaly-1 protein） 無(wú)腦回的致病基因LIS1抗原 0.5mg
46920LFABP/FABP-1（Liver Fatty acid binding protein） 肝臟型脂肪酸結(jié)合蛋白抗原 0.5mg
46921LFABP/FABP-2（Liver Fatty acid binding protein） 肝臟型脂肪酸結(jié)合蛋白抗原 0.5mg
46922LN （laminin） 層粘連蛋白（多肽抗原） 0.5mg
46923Laminin Beta1 peptide 層粘連蛋白β1抗原 0.5mg
46924lamin A 核纖層蛋白A抗原 0.5mg
46925LOX-1/OLR1 凝集素樣氧化型低密度脂蛋白受體 0.5mg
46926LPLUNC1 人鼻咽癌癌基因多肽抗原 0.5mg
46927LYVE-1（lymphalic vessel endotheilial hyaluronan receptor 1） 淋巴管內(nèi)皮透明質(zhì)酸受體抗原 0.5mg
46928ACE（ ACE, testis-specific isoform precursor） 血管緊張素轉(zhuǎn)換酶（抗原） 0.5mg
46929Integrin alpha E2 peptide 整合素alpha E2抗原 0.5mg
46930Mac-1 （Mac-1/CR3/CD11b+CD18） 巨噬細(xì)胞表面分子抗原 0.5mg
46931Mafa（avian）（V-maf musculoaponeurotic fibrosarcoma oncogene homolog A） v-maf 肌腱膜纖維肉瘤癌基因同源物A抗原 0.5mg
46932MAGE-1 黑色素瘤相關(guān) 0.5mg
46933MAPKK1 （MAP kinase kinase 1） 絲裂原活化蛋白激酶激酶1抗原 0.5mg
46934ASK1/MAPKKK5 細(xì)胞凋亡信號(hào)調(diào)節(jié)激酶1/絲裂原活化蛋白激酶激酶激酶5抗原 0.5mg
46935Maspin （mammary serine protease inhibitor） 抑癌基因抗原 0.5mg
46936Matriptase 蛋白裂解酶（一種新的癌基因）抗原 0.5mg
46937HCMV UL49（Human Cytomegalovirus UL49 Gene） 人巨細(xì)胞病毒UL49抗原 0.5mg
46938MC-1R （melanocortin-1-receptor） 黑皮質(zhì)素-1受體抗原 0.5ml
46939Mcl-1（myeloid cell leukemia 1） peptide 髓樣細(xì)胞白血病-1抗原 0.5mg
46940MDM2 （urine double minute 2） 雙微體2癌基因抗原 0.5mg
46941MDR1（multidrug resistance 1） 多藥耐藥蛋白抗原 0.5mg
G蛋白偶聯(lián)受體109A抗體46942MEF2（myocyte enhancer-binding factor 2） 肌細(xì)胞增強(qiáng)因子2抗原 0.5mg
蛋白分子量 predicted molecular weight: 40kDa
性 狀 Lyophilized or Liquid
免 疫 原 KLH conjugated synthetic peptide derived from human GPR109A
亞 型 IgG
純化方法 affinity purified by Protein A
儲(chǔ) 存 液 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodium azide
產(chǎn)品應(yīng)用 IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
（石蠟切片需做抗原修復(fù)）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
保存條件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
Important Note This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.
G蛋白偶聯(lián)受體109A抗體產(chǎn)品介紹 Acts as a high affinity receptor for both nicotinic acid （also known as niacin） and （D）-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G（i）-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis.
Function : Acts as a high affinity receptor for both nicotinic acid （also known as niacin） and （D）-beta-hydroxybutyrate and mediates increased adiponectin secretion and decreased lipolysis through G（i）-protein-mediated inhibition of adenylyl cyclase. This pharmacological effect requires nicotinic acid doses that are much higher than those provided by a normal diet. Mediates nicotinic acid-induced apoptosis in mature neutrophils. Receptor activation by nicotinic acid results in reduced cAMP levels which may affect activity of cAMP-dependent protein kinase A and phosphorylation of target proteins, leading to neutrophil apoptosis. The rank order of potency for the displacement of nicotinic acid binding is 5-methyl pyrazole-3-carboxylic acid = pyridine-3-acetic acid > acifran > 5-methyl nicotinic acid = acipimox >> nicotinuric acid = nicotinamide.
Subcellular Location : Cell membrane; Multi-pass membrane protein.
Tissue Specificity : Expression largely restricted to adipose tissue and spleen. Expressed on mature neutrophils but not on immature neutrophils or eosinophils.
Similarity : Belongs to the G-protein coupled receptor 1 family.
Database links : UniProtKB/Swiss-Prot: Q8TDS4.1